Last reviewed · How we verify

Obeticholic Acid Tablets(OCA) — Competitive Intelligence Brief

Obeticholic Acid Tablets(OCA) (Obeticholic Acid Tablets(OCA)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Farnesoid X receptor (FXR) agonist. Area: Hepatology / Gastroenterology.

phase 3 Farnesoid X receptor (FXR) agonist FXR (Farnesoid X Receptor) Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Obeticholic Acid Tablets(OCA) (Obeticholic Acid Tablets(OCA)) — Nanjing Chia-tai Tianqing Pharmaceutical. Obeticholic acid is a farnesoid X receptor (FXR) agonist that reduces bile acid synthesis and improves liver function by modulating nuclear receptor signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Obeticholic Acid Tablets(OCA) TARGET Obeticholic Acid Tablets(OCA) Nanjing Chia-tai Tianqing Pharmaceutical phase 3 Farnesoid X receptor (FXR) agonist FXR (Farnesoid X Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Farnesoid X receptor (FXR) agonist class)

  1. Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Obeticholic Acid Tablets(OCA) — Competitive Intelligence Brief. https://druglandscape.com/ci/obeticholic-acid-tablets-oca. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: